Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rh-ES + CV
- Development stage
- Preclinical
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
rh-ES + CV is a combination therapy consisting of recombinant human endostatin (rh-ES) and an agent abbreviated as "CV." Recombinant human endostatin is an endogenous broad-spectrum angiogenesis inhibitor, meaning it blocks the formation of new blood vessels that tumors need to grow. It has been shown to significantly improve therapeutic efficacy in cancer treatment when used in combination with other agents. The specific identity of "CV" in this context is not clarified in the available sources, but the combination is under clinical investigation for its anti-tumor effects[1].
- Other names
- recombinant human endostatin + CV
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on rh-ES + CV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rh-ES + CV.